Royalty Pharma plc (NASDAQ: RPRX) kicked off on Friday, down -5.44% from the previous trading day, before settling in for the closing price of $40.78. Over the past 52 weeks, RPRX has traded in a range of $24.05-$41.24.
During the last 5-year period, the sales drop of Healthcare Sector giant was -21.51%. While this was happening, its average annual earnings per share was recorded 10.42%. With a float of $340.69 million, this company’s outstanding shares have now reached $429.03 million.
Royalty Pharma plc (RPRX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Royalty Pharma plc is 21.19%, while institutional ownership is 75.49%. The most recent insider transaction that took place on Aug 11 ’25, was worth 1,213,749. In this transaction Director of this company sold 33,500 shares at a rate of $36.23, taking the stock ownership to the 194,848 shares. Before that another transaction happened on Aug 11 ’25, when Company’s Director proposed sale 33,500 for $36.23, making the entire transaction worth $1,213,747.
Royalty Pharma plc (RPRX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 1.15 earnings per share (EPS), higher than consensus estimate (set at 1.05) by 0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.92% during the next five years compared to -21.51% drop over the previous five years of trading.
Royalty Pharma plc (NASDAQ: RPRX) Trading Performance Indicators
Take a look at Royalty Pharma plc’s (RPRX) current performance indicators. Last quarter, stock had a quick ratio of 3.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.47. Likewise, its price to free cash flow for the trailing twelve months is 8.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.75, a number that is poised to hit 1.27 in the next quarter and is forecasted to reach 4.77 in one year’s time.
Technical Analysis of Royalty Pharma plc (RPRX)
Looking closely at Royalty Pharma plc (NASDAQ: RPRX), its last 5-days average volume was 6.6 million, which is a jump from its year-to-date volume of 4.31 million. As of the previous 9 days, the stock’s Stochastic %D was 76.54%.
During the past 100 days, Royalty Pharma plc’s (RPRX) raw stochastic average was set at 62.57%, which indicates a significant increase from 49.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.20 in the past 14 days, which was higher than the 0.79 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.50, while its 200-day Moving Average is $34.53. However, in the short run, Royalty Pharma plc’s stock first resistance to watch stands at $39.64. Second resistance stands at $40.73. The third major resistance level sits at $41.35. If the price goes on to break the first support level at $37.93, it is likely to go to the next support level at $37.31. Now, if the price goes above the second support level, the third support stands at $36.22.
Royalty Pharma plc (NASDAQ: RPRX) Key Stats
The company with the Market Capitalisation of 22.26 billion has total of 583,174K Shares Outstanding. Its annual sales at the moment are 2,264 M in contrast with the sum of 858,980 K annual income. Company’s last quarter sales were recorded 578,670 K and last quarter income was 30,180 K.
